-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師的觀點總結如下：Vulcan Materials公佈了強勁的2026年第一季業績，調整後每股收益為1.35美元（年成長35%，高於市場預期22.4%），調整後EBITDA為4.47億美元（年成長8.8%，高於市場預期7.9%）。總營收成長7.4%至17.56億美元（高於市場預期8.1%），主要得益於骨材銷售成長5%及價格上漲4%。骨材策略展現成效，單位獲利能力提升，儘管面臨成本壓力，每噸現金毛利仍提高至10.93美元。管理層重申了2026年調整後EBITDA預期為24億至26億美元，理由是市場需求基本面良好且執行動能強勁。投資組合優化包括剝離休士頓瀝青業務和即將完成的加州預拌混凝土業務出售，這與公司專注於高回報骨材業務的策略相符。我們認為，公司穩健的資產負債表（負債與EBITDA比率為1.9倍，並已向股東返還2.17億美元）表明其資本配置均衡，而強大的財務靈活性則為持續創造價值提供了支持。
Related Articles
Research
Research Alert: CFRA Downgrades Rating To Sell From Hold On Shares Of Essex Property Trust, Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target by $15 to $250 using a narrower equity risk premium and a forward P/FFO of 15.5x, which is in line with the multifamily residential REIT average. We keep our 2026 FFO estimate at $16.15 and lower 2027's by $0.05 to $16.45 on respective revenue projections of $1.94B and $1.98B. Rental revenue is not yet rebounding to historical growth levels. Across the industry, we are seeing inflation in key operating expenses exceeding revenue growth, and this leads to modest gains in cash NOI growth Y/Y. We expect these market conditions to continue as pricing power for ESS and its peers seems to have eased. In particular, ESS has a West Coast portfolio profile that is exposed to significant job layoffs in the technology sector. In our opinion, we have not yet seen the tail risk of major announcements just released in recent weeks. ESS has the challenge of complying with strict housing guidelines in California, leading to the trust historically underperforming peers in other parts of the country.
$ESS
Research
Research Alert: CFRA Keeps Buy Rating On Shares Of Biogen Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our target at $236, 13.8x our new 2027 EPS view, a discount to BIIB's five-year historical forward P/E average of 14.1x. We lower our 2026 EPS view to $15.24 from $16.14 to adjust for the impact from acquired IPR&D. We keep our 2027 EPS view at $17.16. BIIB reported a strong start to 2026, with sales of $2.5B and adjusted EPS of $3.57. We see a successful stabilization of the business after years of decline, due to a 12% Y/Y increase in the growth products portfolio. In our view, during the analyst call, management presented a clear strategic vision centered on the pending $5.6B acquisition of Apellis, expected to close in Q2, which can transform BIIB into a growth company by adding two commercial assets, Syfovre and Empaveli. We think the Apellis deal could bridge a revenue gap until 2028, when the company's late-stage pipeline matures. Via this acquisition, BIIB also gains nephrology expertise and an established infrastructure, which could set its key asset Felzartamab launch for success.
$BIIB
Australia
Starbucks to Sustain Sales Momentum; to Focus on Margins in H2, UBS Says
Starbucks (SBUX) is expected to maintain solid sales momentum on its turnaround strategy, though investor focus is shifting toward margin recovery in H2, UBS said in a note on Wednesday.The brokerage said strong transaction-driven comparable sales growth in Q2 reflected improvements in operations, menu innovation and updated loyalty program.Looking ahead, UBS said continued execution on initiatives such as afternoon beverage platforms, loyalty enhancements, store closures and operational improvements should support sales into H2.UBS also expects margin expansion later in the year, supported by sales leverage, cost savings and easing pressures from tariffs and coffee costs.UBS raised the price target on the stock to $105 from $100 but maintained a neutral rating.Price: $106.10, Change: $+8.82, Percent Change: +9.06%
$SBUX